ADVM 053

Drug Profile

ADVM 053

Alternative Names: ADVM-053; ANN 002

Latest Information Update: 07 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Weill Cornell Medical College
  • Developer Adverum Biotechnologies
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hereditary angioedema

Most Recent Events

  • 08 Nov 2017 Adverum Biotechnologies plans to file an IND application with the US FDA in USA for Hereditary angioedema in the second half of 2018
  • 06 Mar 2017 Adverum plans IND-enabling toxicology studies for Hereditary angioedema and intends to enter into a discussion with US FDA in the first half of 2017
  • 06 Jan 2017 Preclinical trials in Hereditary angioedema in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top